HLHong Liu

Hong Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Hong Liu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Dan Liu

    Cancer Institute Longhua Hospital Shanghai University of Traditional Chinese Medicine Shanghai China

    1 shared publication
  • Jibin Liu

    Institute of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu 226361, P.R. China

    1 shared publication
  • Lei Liu

    Department of Thoracic Surgery The Affiliated Tumor Hospital of Nantong University Nantong China

    1 shared publication
  • Li Feng

    National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy for Medical Sciences and Peking Union Medical College Beijing China

    1 shared publication
  • Ling Gao

    Cancer Institute Longhua Hospital Shanghai University of Traditional Chinese Medicine Shanghai China

    1 shared publication
  • Mingsong Wang

    Shanghai Ninth Peoples Hospital, Shanghai Jiaotong University, Shanghai, China

    1 shared publication

Latest Publications

  • Open Access

    Fibrillarin Resists Cellular Senescence Via SIRT1‐Dependent Nicotinamide Metabolism and Its Inhibition Sensitizes Senolytic Therapy in Esophageal Squamous Cell Carcinoma

    by Xing Jin, Hong Liu, Ling Gao, Lei Liu, Ji‐Bin Liu, Xiaoxia Jin, Ming‐Song Wang, Dan Liu, Li Feng, Wen‐Lian Chen

    The importance of fibrillarin (FBL), an established nucleolar methyltransferase, was identified in neoplastic growth of esophageal squamous cell carcinoma (ESCC), one of the most lethal malignancies worldwide. However, the underlying mechanism remains unclear. Here, by enrolling independent ESCC cohorts, we verified the negative correlation between intratumoral FBL expression and patient prognosis. Notably, comprehensive transcriptomic and metabolomic analyses indicated that FBL deletion elicited cell cycle arrest and cellular senescence, as well as block of nicotinamide metabolism and increase of oxidative stress. Mechanistically, FBL could bind to and stabilize SIRT1 by obstructing the ubiquitin‐proteasome‐mediated protein degradation, therefore provoking nicotinamide metabolism, sustaining redox homeostasis, and counteracting senescence. Clinically, FBL‐SIRT1 axis was augmented in tumor tissues of ESCC patients, and high intratumoral SIRT1 expression predicted poor patient survival. Finally, we found that both genetic and pharmacological inhibition of FBL could sensitize senolytic therapy for ESCC. In conclusion, we first discovered FBL as an anti‐senescent protein in tumor progression. FBL resists cellular senescence by stabilizing SIRT1 and sustaining the nicotinamide metabolism, therefore providing an optional strategy for ESCC treatment by sensitizing senolytic therapy with FBL inhibitors.